Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luc-Matthieu Fornecker

Showing results (21-30 of 77) with videos related to

Pageof 8
Sort By:
Blood Advances|November 14, 2025
Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disordersLaurent Mauvieux, Raoul Herbrecht, Alice Eischen, et al.
Frontiers in Immunology|February 4, 2025
Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccineSylvain Lamure, Houria Hendel Chavez, Marie-Ghislaine de Goër de Herve, et al.
American Journal of Hematology|March 11, 2015
Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experienceLuc-Matthieu Fornecker, Thérèse Aurran-Schleinitz, Anne-Sophie Michallet, et al.
Blood Cancer Journal|November 3, 2025
Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trialsValentin Letailleur, Isabelle Chaillol, Fanny Cherblanc, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 28, 2023
Association Between Bruton's Tyrosine Kinase Gene Overexpression and Risk of Lymphoma in Primary Sjögren's SyndromePierre-Marie Duret, Cedric Schleiss, Lou Kawka, et al.
British Journal of Haematology|April 4, 2018
Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA studyBenedicte Deau, Sandy Amorim, Aurore Perrot, et al.
American Journal of Hematology|March 16, 2017
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) groupAnne-Sophie Michallet, Arnaud Campidelli, Helene Lequeu, et al.
Scientific Reports|January 26, 2019
BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivoCédric Schleiss, Wassila Ilias, Ouria Tahar, et al.
European Radiology|June 21, 2018
Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?Aikaterini Fitsiori, Luc-Matthieu Fornecker, Laurence Simon, et al.
Blood|June 28, 2019
Prevalence of <i>BTK</i> and <i>PLCG2</i> mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group studyAnne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, et al.
Pageof 8

Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Blood Advances|November 14, 2025
Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disordersLaurent Mauvieux, Raoul Herbrecht, Alice Eischen, et al.
Frontiers in Immunology|February 4, 2025
Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccineSylvain Lamure, Houria Hendel Chavez, Marie-Ghislaine de Goër de Herve, et al.
American Journal of Hematology|March 11, 2015
Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experienceLuc-Matthieu Fornecker, Thérèse Aurran-Schleinitz, Anne-Sophie Michallet, et al.
Blood Cancer Journal|November 3, 2025
Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trialsValentin Letailleur, Isabelle Chaillol, Fanny Cherblanc, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 28, 2023
Association Between Bruton's Tyrosine Kinase Gene Overexpression and Risk of Lymphoma in Primary Sjögren's SyndromePierre-Marie Duret, Cedric Schleiss, Lou Kawka, et al.
British Journal of Haematology|April 4, 2018
Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA studyBenedicte Deau, Sandy Amorim, Aurore Perrot, et al.
American Journal of Hematology|March 16, 2017
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) groupAnne-Sophie Michallet, Arnaud Campidelli, Helene Lequeu, et al.
Scientific Reports|January 26, 2019
BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivoCédric Schleiss, Wassila Ilias, Ouria Tahar, et al.
European Radiology|June 21, 2018
Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?Aikaterini Fitsiori, Luc-Matthieu Fornecker, Laurence Simon, et al.
Blood|June 28, 2019
Prevalence of <i>BTK</i> and <i>PLCG2</i> mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group studyAnne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, et al.
Pageof 8